Abbvie Inc. ABBV

Revenue Intelligence Report • 56 quarters of SEC filing data • Updated 2026-03-06

Abbvie Inc. has demonstrated a strong correlation between its selling, general, and administrative (SG&A) expenses and revenue growth, with a 1% increase in SG&A resulting in a 1.01% rise in revenue, indicating effective spending strategies. The company's latest quarterly revenue of $16,618 million reflects its robust market position, supported by a solid model accuracy of 5.3% MAPE and a successful holdout test predicting revenues with only a 4.1% error. Looking ahead, Abbvie is projected to achieve $65 billion in revenue for the fiscal year, representing a 6.6% year-over-year growth, showcasing a positive outlook for investors. This combination of strategic spending and revenue growth positions Abbvie as a compelling investment opportunity.

Next FY Revenue

$65.22B

+6.6% YoY

SG&A Elasticity

1.01x

Model Accuracy

5.3% MAPE

Holdout validation: The model predicted $16B vs the actual $17B — an error of 4.1%.

Note: Abbvie Inc. does not report R&D expenses separately. This analysis uses SG&A spending only.

Revenue Forecast

Quarterly Detail

Quarter	Model Forecast	Actual	95% Range	YoY Growth	Status
Q4 2025	$16B	$17B	$14B – $18B	+5.5%	✓ In range
Q2 2026	$16B		$13B – $20B	+20.6%
Q3 2026	$16B		$13B – $21B	+5.3%
Q4 2026	$16B		$12B – $22B	+3.8%
Q1 2027	$17B		$12B – $23B	-0.6%

How Spending Drives Revenue

Reading this chart: Each line shows the cumulative elasticity — how a 1% increase in spending translates to revenue growth over subsequent quarters. The effect builds over 4-5 quarters as investments compound.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch